“The positive results from this confirmatory patient study represent an important step in the development of the Xolair® biosimilar candidate. We look forward to working with our partners to increase ...

MorningStar Laboratories, LLC., (“MSL” or “the Company”), is a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce its expansion in the Midwest with ...

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care ...

Houston, TX, June 24, 2025 (GLOBE NEWSWIRE) -- Shiny Smile Veneers, a US-based provider of custom-made snap-on veneers, has ...

D-Bal – Mimicking the effects of Dianabol, D-Bal boosts nitrogen retention and protein synthesis for rapid muscle growth.

Lulutox Detox Tea officially launches across Ireland, the USA, UK, Australia and Canada. Formulated with natural herbs like ...

LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park En cliquant sur ce lien, vous acceptez l'utilisation de cookies sur ce site internet.

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and ...

Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the ...

Addex shareholders approved the 2024 annual report, the 2024 annual financial statements, the appropriation of the results as well as the compensation report (the latter in a consultative vote). All ...

OSE Immunotherapeutics will keep the market and its shareholders informed of the outcome of the proceedings initiated and described in its press release dated June 20, 2025 1. The Company also notes ...

Allschwil, Switzerland – June 25, 2025 Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 million convertible bonds maturing in 2025 ( ...